keyword
https://read.qxmd.com/read/38074147/comparison-of-the-effects-of-fentanyls-and-other-%C3%AE-opioid-receptor-agonists-on-the-electrical-activity-of-respiratory-muscles-in-the-rat
#1
JOURNAL ARTICLE
Damiana Cavallo, Eamonn Kelly, Graeme Henderson, Ana Paula Abdala Sheikh
Introduction: Deaths due to overdose of fentanyls result primarily from depression of respiration. These potent opioids can also produce muscle rigidity in the diaphragm and the chest muscles, a phenomenon known as Wooden Chest Syndrome, which further limits ventilation. Methods: We have compared the depression of ventilation by fentanyl and morphine by directly measuring their ability to induce muscle rigidity using EMG recording from diaphragm and external and internal intercostal muscles, in the rat working heart-brainstem preparation...
2023: Frontiers in Pharmacology
https://read.qxmd.com/read/37864951/development-of-a-novel-enantioselective-high-performance-liquid-chromatography-mass-spectrometry-method-for-the-differentiation-of-dextro-and-levo-methorphan-and-their-o-demethylated-metabolites-in-human-blood-and-its-application-to-post-mortem-samples
#2
JOURNAL ARTICLE
Saba Jorbenadze, Tamar Khatiashvili, Aluda Chelidze, Alfredo Fabrizio Lo Faro, Tivadar Farkas, Anastasio Tini, Giorgia Sprega, Diletta Berardinelli, Francesco Paolo Busardò, Bezhan Chankvetadze
Recently we proposed an isocratic enantioselective high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the separation and quantitative determination of dextro- (DXM) and levo-methorphan (LVM) and their pharmacologically relevant metabolites, dextrorphan and levorphanol, respectively, in human blood samples. This method was based on the polysaccharide-based chiral column Lux AMP, a specialty column characterized with high stability in mobile phases of pH 11.0 and above. The use of a single-source column is a limitation for any analytical method...
October 5, 2023: Journal of Pharmaceutical and Biomedical Analysis
https://read.qxmd.com/read/37044005/development-of-an-enantioselective-high-performance-liquid-chromatography-tandem-mass-spectrometry-method-for-the-quantitative-determination-of-methorphan-and-its-o-demethylated-metabolite-in-human-blood-and-its-application-to-post-mortem-samples
#3
JOURNAL ARTICLE
Alfredo Fabrizio Lo Faro, Diletta Berardinelli, Giorgia Sprega, Anastasio Tini, Jeremy Carlier, Tivadar Farkas, Francesco Paolo Busardò, Bezhan Chankvetadze
In the present work an isocratic enantioselective high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed for the separation and quantitative determination of dextro - and levo -methorphan and their pharmacologically relevant metabolites, dextrorphan and levorphanol, respectively, in human blood samples. The separation of enantiomers of methorphan and metabolites was performed on the polysaccharide-based chiral column Lux AMP in combination with acetonitrile and 5 mM aqueous ammonium bicarbonate pH 11 in the ratio 50:50 (%, v/v) as mobile phase with the flow rate 1 mL/min...
March 31, 2023: Journal of Pharmaceutical and Biomedical Analysis
https://read.qxmd.com/read/36720398/levorphanol-as-a-second-line-opioid-in-cancer-patients-presenting-to-an-outpatient-supportive-care-center-an-open-label-study
#4
JOURNAL ARTICLE
Akhila Reddy, Ali Haider, Joseph Arthur, David Hui, Shalini Dalal, Rony Dev, Kimberson Tanco, Jaya Amaram-Davila, Farley Hernandez, Paul Chavez, Aline Rozman De Moraes, Jimin Wu, Kristy Nguyen, Ishwaria Subbiah, Daniel Epner, Zeena Shelal, Marvin Omar Delgado Guay, Tarun Mallipeddi, Eduardo Bruera
CONTEXT: Levorphanol is a potent opioid agonist and NMDA receptor blocker with minimal drug interactions, and there are few reports of its use in cancer patients. OBJECTIVES: We aimed to determine the frequency of successful opioid rotation (OR) to levorphanol and the median opioid rotation ratio (ORR) from Morphine Equivalent Daily Dose (MEDD). METHODS: This is a prospective, single-group, interventional study. Cancer outpatients requiring an OR and receiving a MEDD of 60-300 mg were rotated to levorphanol using a ratio of 10:1 and assessed daily for 10-day...
June 2023: Journal of Pain and Symptom Management
https://read.qxmd.com/read/36541939/comparison-table-some-oral-transdermal-opioid-analgesics
#5
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
December 12, 2022: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/36541938/opioids-for-pain
#6
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
December 12, 2022: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/35559657/a-comparison-of-institutional-opioid-equianalgesia-tools-a-national-study
#7
JOURNAL ARTICLE
Raymond Y Wen, Rabia S Atayee, Kyle P Edmonds
Context: Equianalgesic tools are commonly utilized to guide dose of analgesic therapy, but there is no national consensus on equianalgesic calculations in the United States. Objectives: To propose a summary of current opioid equianalgesic data that include variations and trends among national institutions. Methods: Opioid equianalgesic tools were obtained between May and September 2021. For meperidine, tramadol, codeine, hydrocodone, morphine, oxycodone, oxymorphone, hydromorphone, levorphanol, fentanyl, and tapentadol, details of adjustment for incomplete tolerance, opioid equianalgesic ratios, and formulation types were collected and analyzed...
November 2022: Journal of Palliative Medicine
https://read.qxmd.com/read/33630185/tapentadol-buprenorphine-and-levorphanol-for-the-treatment-of-neuropathic-pain-a-systematic-review
#8
JOURNAL ARTICLE
Samantha C Erosa, Paul R Haffey, Neel Mehta, Amitabh Gulati
PURPOSE OF REVIEW: The objective of this systematic review is to present the available evidence for the utilization of the atypical opioids tapentadol, buprenorphine, and levorphanol for the treatment of neuropathic pain. RECENT FINDINGS: In total, 1619 articles were retrieved of which 10 studies were included. Of 5 included studies pertaining to tapentadol, 4 studies show tapentadol monotherapy to be effective for the treatment of diabetic peripheral neuropathy or chronic, radiating low back pain...
February 25, 2021: Current Pain and Headache Reports
https://read.qxmd.com/read/33154662/levorphanol-in-the-perioperative-setting-decreasing-opioid-requirements-while-improving-pain-management
#9
REVIEW
Christopher R Page, Carlos Andres Perez, Ana Mavarez-Martinez, Sara Khan, Sergio D Bergese
Levorphanol is a Food and Drug Administration (FDA)-approved long-acting opioid. Most information on perioperative use of levorphanol comes from the early- and mid-1950s when this drug emerged in the field of experimental pharmacology and anesthesia. It was mainly studied during this period with some additional data being generated in the 1960s and 70s. Since this time, perioperative use has declined and research is limited. This review of literature aims to provide pharmacologic and historic description of levorphanol as a tool for perioperative pain management and as an aid to potentially decrease total postoperative opioid use during the current opioid crisis...
2020: Journal of Pain Research
https://read.qxmd.com/read/33004158/a-comprehensive-review-of-partial-opioid-agonists-for-the-treatment-of-chronic-pain
#10
REVIEW
Kyle Gress, Karina Charipova, Jai Won Jung, Alan D Kaye, Antonella Paladini, Giustino Varrassi, Omar Viswanath, Ivan Urits
Chronic pain is a common condition that is being increasingly recognized, diagnosed, and treated in a variety of settings. Opioids can be used to treat chronic pain but at the cost of adverse effects and risk of dependence. Recently, there has been a movement to improve analgesic care in the setting of the opioid epidemic and the overprescribing of opioids, causing over-accessibility, dependence, and large numbers of overdose deaths. Opioid-specific receptors, including the μ, δ, κ, and opioid receptor like-1 (ORL-1) receptors, are each 7-transmembrane spanning proteins, which affect the G-protein and β-arrestin cascades...
September 2020: Best Practice & Research. Clinical Anaesthesiology
https://read.qxmd.com/read/32156130/levorphanol-versus-methadone-use-safety-considerations
#11
REVIEW
Ali Haider, Akhila Reddy
Methadone has unique characteristics that make it an attractive agent for the treatment of chronic pain and opioid drug dependence. However, methadone prescription requires more clinical experience and close monitoring of patients to avoid its undesirable side effects. Recently, levorphanol has emerged as "a forgotten opioid" with a similar profile as methadone. Levorphanol has no impact on QTc prolongation and considerably less drug-drug interactions as compared to methadone. Lack of commercial availability, providers' unfamiliarity, and limited clinical data on its effectiveness remain practical issues...
March 2020: Annals of Palliative Medicine
https://read.qxmd.com/read/31413473/levorphanol-rewinding-an-old-bygone-multimodal-opioid-analgesic
#12
JOURNAL ARTICLE
Abhijit S Nair, Omkar Upputuri, Srinivasa Shyam Prasad Mantha, Basanth Kumar Rayani
No abstract text is available yet for this article.
July 2019: Indian Journal of Palliative Care
https://read.qxmd.com/read/29649035/pharmacological-characterization-of-levorphanol-a-g-protein-biased-opioid-analgesic
#13
JOURNAL ARTICLE
Valerie Le Rouzic, Ankita Narayan, Amanda Hunkle, Gina F Marrone, Zhigang Lu, Susruta Majumdar, Jin Xu, Ying-Xian Pan, Gavril W Pasternak
BACKGROUND: Levorphanol is a potent analgesic that has been used for decades. Most commonly used for acute and cancer pain, it also is effective against neuropathic pain. The recent appreciation of the importance of functional bias and the uncovering of multiple µ opioid receptor splice variants may help explain the variability of patient responses to different opioid drugs. METHODS: Here, we evaluate levorphanol in a variety of traditional in vitro receptor binding and functional assays...
February 2019: Anesthesia and Analgesia
https://read.qxmd.com/read/29565959/identifying-levorphanol-ingestion-using-urine-biomarkers-in-health-care-patients
#14
JOURNAL ARTICLE
Amber R Watson, Ali Roberts
BACKGROUND: Levorphanol is a long-acting opioid analgesic that is an optical isomer of dextrorphan, a metabolite of the over-the-counter cough suppressant dextromethorphan. Providers prescribing levorphanol for pain management may need to assess compliance through urine drug testing, as this agent is subject to abuse. Therefore, it is important to differentiate between dextromethorphan and levorphanol ingestion. OBJECTIVES: This article is the first to report urine concentrations of levorphanol/dextrorphan and 3-hydroxymorphinan in human urine and assesses the need for an enantiomeric analysis to distinguish between dextromethorphan and levorphanol ingestion...
March 2018: Pain Physician
https://read.qxmd.com/read/29377758/levorphanol-for-treatment-of-intractable-neuropathic-pain-in-cancer-patients
#15
JOURNAL ARTICLE
Akhila Reddy, Amy Ng, Tarun Mallipeddi, Eduardo Bruera
Neuropathic pain in cancer patients is often difficult to treat, requiring a combination of several different pharmacological therapies. We describe two patients with complex neuropathic pain syndromes in the form of phantom limb pain and Brown-Sequard syndrome who did not respond to conventional treatments but responded dramatically to the addition of levorphanol. Levorphanol is a synthetic strong opioid that is a potent N-methyl-d-aspartate receptor antagonist, mu, kappa, and delta opioid receptor agonist, and reuptake inhibitor of serotonin and norepinephrine...
March 2018: Journal of Palliative Medicine
https://read.qxmd.com/read/29084357/adverse-events-associated-with-medium-and-long-term-use-of-opioids-for-chronic-non-cancer-pain-an-overview-of-cochrane-reviews
#16
REVIEW
Charl Els, Tanya D Jackson, Diane Kunyk, Vernon G Lappi, Barend Sonnenberg, Reidar Hagtvedt, Sangita Sharma, Fariba Kolahdooz, Sebastian Straube
BACKGROUND: Chronic pain is common and can be challenging to manage. Despite increased utilisation of opioids, the safety and efficacy of long-term use of these compounds for chronic non-cancer pain (CNCP) remains controversial. This overview of Cochrane Reviews complements the overview entitled 'High-dose opioids for chronic non-cancer pain: an overview of Cochrane Reviews'. OBJECTIVES: To provide an overview of the occurrence and nature of adverse events associated with any opioid agent (any dose, frequency, or route of administration) used on a medium- or long-term basis for the treatment of CNCP in adults...
October 30, 2017: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/28916251/mk-801-but-not-naloxone-attenuates-high-dose-dextromethorphan-induced-convulsive-behavior-possible-involvement-of-the-glun2b-receptor
#17
JOURNAL ARTICLE
Hai-Quyen Tran, Yoon Hee Chung, Eun-Joo Shin, The-Vinh Tran, Ji Hoon Jeong, Choon-Gon Jang, Seung-Yeol Nah, Kiyofumi Yamada, Toshitaka Nabeshima, Hyoung-Chun Kim
Dextromethorphan (DM) is a dextrorotatory isomer of levorphanol, a typical morphine-like opioid. When administered at supra-antitussive doses, DM produces psychotoxic and neurotoxic effects in humans. Although DM abuse has been well-documented, few studies have examined the effects of high-dose DM. The present study aimed to explore the effects of a single high dose of DM on mortality and seizure occurrence. After intraperitoneal administration with a high dose of DM (80mg/kg), Sprague-Dawley rats showed increased seizure occurrence and intensity...
November 1, 2017: Toxicology and Applied Pharmacology
https://read.qxmd.com/read/28162375/-153-levorphanol-another-choice-in-opioid-rotation
#18
JOURNAL ARTICLE
S Nalamachu, J Gudin
No abstract text is available yet for this article.
April 2016: Journal of Pain
https://read.qxmd.com/read/26635068/levorphanol-use-past-present-and-future
#19
REVIEW
Jeffrey Gudin, Jeffrey Fudin, Srinivas Nalamachu
Levorphanol is a potent opioid analgesic that was first approved for use in the United States in 1953. Levorphanol is approved for use in moderate to severe pain where an opioid analgesic is appropriate. Levorphanol has a wide range of activities including mu opioid agonism, delta agonism, kappa1 and kappa3 receptor agonism, N-methyl-d-aspartate receptor antagonism and reuptake inhibition of both norepinephrine and serotonin. This multimodal profile might prove effective for pain syndromes that are refractory to other opioid analgesics, such as central and neuropathic pain and opioid-induced hyperalgesia...
January 2016: Postgraduate Medicine
https://read.qxmd.com/read/26307179/is-levorphanol-a-better-option-than-methadone
#20
REVIEW
Thien C Pham, Jeffrey Fudin, Robert B Raffa
BACKGROUND: Methadone has been a stalwart pharmacologic option for the management of opioid drug dependence for many years. It substitutes for opioid agonists and possesses certain pharmacokinetic properties that confer characteristics preferable to those of other opioids for this application. Methadone is likewise used as an option for the treatment of pain, particularly chronic pain. It has a spectrum of pharmacodynamic activity, including contributions from non-opioid components, that translates to its specific clinical attributes as an analgesic...
September 2015: Pain Medicine
keyword
keyword
63015
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.